In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: November 2025
Friends, As we approach the end of the year, one thing stands out above all else: this is a moment of unprecedented opportunity to accelerate progress against ovarian and all gynecologic cancers. And thanks to you, OCRA is rising to meet that moment — driving innovation, expanding support, and providing the community that so many … Continued
OCRA Board Member Laura Shawver, PhD, Named to Fierce 50 of 2025
Ovarian Cancer Research Alliance (OCRA) congratulates board member Laura Shawver, PhD, on her selection to the Fierce 50 of 2025, a leading industry award from Fierce Life Sciences recognizing individuals and organizations advancing what’s possible in health, science and patient care. Dr. Shawver was selected for her long-standing leadership in oncology research and drug development, … Continued
Make 2X the Difference with OCRA on GivingTuesday
On GivingTuesday, YOU Can Help Shape the Future of Ovarian and Gynecologic Cancer Care GivingTuesday gifts—including early gifts—will be matched by a generous OCRA board member, dollar for dollar, up to $500,000. That means your $1 = $2 to improve care, foster hope, and bring us closer to a cure. Ovarian Cancer Research Alliance (OCRA) … Continued